EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 722 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer August 2, 2021 HGTV Star Hilary Farr Shares Breast Cancer Battle December 16, 2021 Medicare Open Enrollment is Almost Here-What You Need to Know for... October 13, 2020 Load more HOT NEWS Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... Coming together for Zynlonta FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast...
